Migraine is a highly disabling disorder that affects hundreds of millions of people around the world. Yet, a little number of prophylactic treatments are available still now. The limited number of available drugs leads to a wide use of nutraceutical compounds in migraine therapy. To improve the efficacy, some of these nutraceuticals were combined. So far, we do not know if these combinations are really more effective than the single compounds alone, or an anti-synergic effect could be present because of a reciprocal antagonism of effects. For this reason, we decided to test the efficacy of a fixed combination of magnesium, partenium, andrographis, co-enzyme Q10 and riboflavin (PACR) as prophylactic treatment for migraine in a randomized controlled double blind study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
82
Daily assumption of PACR for a 3-month period
Daily assumption of placebo
Policlinico Umberto I
Rome, Italy
RECRUITINGMigraine improvement in terms of responder rate
Number of subjects that at least have a reduction of 50% in terms of migraine frequency
Time frame: 3 months
Migraine improvement in terms of frequencies
reduction of migraine in terms of number of attacks, headache days, and number of analgesics per month.
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.